cancer therapies news from FierceBiotech
News
FDA's Pazdur offers advice to cancer drug developers
Anyone looking for some insight into the way the FDA is examining new cancer therapies should check out the interview BusinessWeek has published with Dr. Richard Pazdur, director of the FDA's Office Read more...
Pfizer gets new cancer team to advance key drugs
With the clock ticking on its patent for Lipitor, Pfizer has turned to a group of new executives to Read more...
Report: Wilex, GPC nearing merger pact
Two German biotech companies which share a very big investor are preparing to merge, according to a prominent German newspaper. Wilex and GPC Biotech, both involved in developing new cancer Read more...
Takeda makes $8.8B bid for Millennium
Looking to expand out of a budget-bound Japanese market, Takeda is taking a big chunk of its $10 billion war chest and offering $8.8 billion in cash for U.S.-based Read more...
Takeda makes $8.8B bid for Millennium
Looking to expand out of a budget-bound Japanese market, Takeda is taking a big chunk of its $10 billion war chest and offering $8.8 billion in cash for U.S.-based Read more...
ALSO NOTED: Crucell shares up on TB data; Celera, Merck ink cancer deal; and much more...
> A federal patent office may appeal a court ruling that threw out a new cap limiting the number of times a company can resubmit patent applications. That change was aggressively contested by the Read more...
Boehringer boasts of late-stage drug potential
A new self-assessment from Boehringer Ingelheim comes with some considerable boasting about the potential for new therapies and new indications now in its pipeline. Read more...
Pfizer halts Phase III cancer trial on poor results
Pfizer's big push into cancer drugs has hit a snag. The company announced that it is halting a late-stage trial of tremelimumab for advanced melanoma after researchers concluded it was no more Read more...
SGX shares slide on report of early-stage toxicity
Shares of SGX Pharmaceuticals were sliding this morning on the news that its lead cancer therapy Read more...
Kosan axes staffers (again), scouts for partners
Kosan Biosciences is laying off more than a third of its 91 workers as the developer concentrates its resources around its lead cancer therapies in a restructuring that has also shuffled its newly Read more...
Paid Research Reports
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
- The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends